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ABSTRACT Toll-like receptors are the essential components of innate immunity. It is shown that TLRs play an 
essential role in the immune resistance of an organism to bacterial and viral infections. The binding of TLR to 
its own ligands results in the activation of several adapter molecules and kinases, inducing the activation of the 
main pro-inflammatory transcriptional factors, which in turn induce the activation of the main pro-inflam-
matory transcriptional factors. This activation results in the development of both the innate immune response 
triggered by the enhanced expression of a number of pro-inflammatory cytokines and antimicrobial peptides 
and that of the adaptive immune response, via the activation of dendritic cells and enhancement of antigen 
presentation, etc. The ability of TLR agonists to bolster the immune reaction makes them promising for use in 
the therapy of infectious diseases and in the chemotherapy of malignant neoformations. However, different TLR 
ligands may have either antitumor activity (lipopolysaccharide, imiquimod, CpG) or, conversely, could beef up 
the resistance of tumor cells to apoptosis, stimulating their proliferation under certain conditions (lipopolysac-
charide, lipopeptide). It has been shown that the TLR2-dependent signalling pathway in the myelomonocytic 
mouse leukaemia cell line WEHI-3B leads to the constitutive activation of the transcriptional factor NF-kB, 
suppression of apoptosis in tumor cells, and progression of myelomonocytic mouse leukaemia in vivo, upon 
the addition of TLR2 agonist (synthetic lipopeptide Pam2CSK4) or following the infection of tumor cells with 
Mycoplasma arginini. 
KEYWORDS Toll-like receptor 2; synthetic diacylated lipopeptide Pam2CSK4; mouse myelomonocytic leukaemia 
cells WEHI-3B; transcription factor NF-kB; apoptosis; tumor progression.
ABBREVIATIONS TLR2 – Toll-like receptor 2; NF-kB – nuclear transcription factor-kB; PAMP – pathogen-asso-
ciated molecular pattern; DAMP – damage-associated molecular pattern; ssRNA – single-stranded ribonucleic 
acid; RT-PCR – reverse transcription polymerase chain reaction; TNF-α – tumor necrosis factor α; IL – inter-
leukin; MCP1– monocyte chemoattractant protein 1.
INTRODUCTION
It is known that toll-like receptors (tLrs) are the cru-
cial components of innate immunity and that they 
participate in the recognition of conserved pathogen-
associated molecular patterns (PAMPs) and damage-
associated molecular patterns (DAMPs) [1, 2]. the in-
teraction between bacterial structures or DAMPs and 
specific toll-like receptors initiates the development of 
reactions of both the innate and adaptive immune re-
sponses to induce the elimination of the causative agent 
from the organism [3, 4].
At the moment, thirteen human toll-like receptors 
(tLr–13) are known. the majority of them are located 
on the surface of various immune cells (macrophagues, 
dendritic cells and mast cells, neutrophils, B-cells and 
t-cells, natural killer cells) and on nonimmune cells, 
such as fibroblasts, epithelial cells, keratinocytes, etc. 
[5–7]. the interaction between tLr and specific lig-
ands initiates a cascade of signals originating from 84 | ActA nAturAe |  VOL. 3  № 4 (11)  2011
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the cytoplasmic tIr domains of tLr [8]. the signal 
proceeds from the tIr domain through the adaptor 
molecules MyD88 (myeloid differentiation factor 88), 
tIrAP (tIr-domain-containing adaptors), tIcAM1 
(trIF), tIcAM2 (tIr-containing adaptor molecule) to 
the corresponding kinases (tAK, IKK, tBK, MAPK, 
JnKs, p38, er K, Akt, etc.), providing differential ac-
tivation of the transcription factors (nF-kB, AP-1, and 
IrF) that are responsible for the expression of various 
pro-inflammatory and antimicrobial factors (IL-6, IL-8, 
tnF, IL-1β), as well as for the activation of antigen-
presenting cells [7, 9].
tLr have been shown to play a key role in the 
regulation of the adaptive immune response. thus, 
the tLr-dependent activation of antigen-presenting 
dendritic cells is a crucial moment in several processes 
that are essential for the development of  adaptive im-
munity, such as for the activation of mature t-cells; 
for the processing and presentation of microbial an-
tigens; for boosting the expression of costimulatory 
molecules (СD80, cD86), which is required for the ac-
tivation of naive cD4+-t-cells; and for the suppres-
sion of regulatory t-cells via IL-6 production [8, 10]. 
It was also discovered that tLr-dependent activation 
is essential for B-cell maturation during the infection 
process [11]. thus, tLr play a significant role in the 
organism, a role that consists in the development of 
inflammatory reactions (activation of the innate im-
mune system) in response to various pathogens (pro-
tozoa, fungi, bacteria, and viruses) entering the or-
ganism [12].
the impact the expression and activation of toll-
like receptors has on tumor progression is currently a 
subject of wide-ranging discussion. It has been dem-
onstrated that tLr can have a dual effect on tumor 
cells, depending on the following factors: tLrs or their 
ligands type, tumor type, administration method, and 
ligand concentration [13]. On the one hand it has been 
shown that tLr can activate an anti-tumor immune re-
sponse [14, 15]. numerous tLr agonists are currently in 
clinical trials for prospective application as anti-tumor 
agents. thus, the natural (ssrnA) and synthetic (imiq-
uimod) tLr7 and tLr8 agonists have a demonstrable 
high activity with respect to chronic lymphocytic leu-
kaemia and skin cancer [16]. the tLr9 – cpG ligand 
is capable of suppressing the development of lympho-
mas, as well as brain, kidney, and skin cancer [14]. the 
tLr3 – poly(Ic) ligand possesses proapoptotic activity 
not only against tumor cells, but also against the cells 
surrounding the tumor (e.g., endothelial cells).
However, despite the existing data on the anti-tu-
mor activity of tLr agonists, numerous studies have 
recently been published that demonstrate that tLr 
ligands can enhance the progression of different types 
of tumors [15–17]. the tLr level is known to be high 
in various tumor cells; the frequency of induced tu-
mor formation is decreased in tLr-knockout mice [18]. 
Furthermore, the boost in tLr expression on the cell 
surface of prostate tumors or head and neck tumors 
lead to an increase of the proliferation rate of these 
cells [19, 20]. Huang et al. [20] demonstrated that Liste-
ria monocytogenes possesses a direct tumor-stimulating 
effect associated with its ability to activate tLr2-de-
pendent signal pathways in ovarian cancer cells. In ad-
dition, the tLr2-dependent activation of nF-kB in-
duced by L. monocytogenes has been shown to increase 
the resistance of tumor cells to the action of chemother-
apeutic agents [16]. the relationship between tLr2 and 
tumor progression was confirmed by Karin et al. [21], 
who proved that this receptor plays the key role in the 
metastasis of lung cancer.
thus, the dual effect of tLr indicates that its func-
tional role in tumor biology is most complex, and that 
it requires a systematic investigation based on various 
models. 
An analysis of the tLr2 expression in various tu-
mor cell lines was carried out in our laboratory. It was 
shown, using the model of the myelomonocytic mouse 
leukaemia cell line WeHI-3B, that the activation of the 
tLr2-dependent signalling pathway leads to apoptosis 
suppression and enhanced tumor growth in vivo, fol-
lowing the enjection of synthetic diacylated lipopeptide 
Pam2cSK4. A similar effect was observed for WeHI-
3B cells infected with Mycoplasma arginini. It was re-
vealed that micoplasma infection or the addition of the 
tLr2 agonist – diacylated lipopeptide Pam2cSK4 – to 
WeHI-3B cells results in the tLr2-dependent activa-
tion of the nF-kB transcription factor in tumor cells 
and the suppression of apoptosis induced by the action 
of various anti-tumor agents. Moreover, it was dem-
onstrated on a model of myelomonocytic mouse leu-
kaemia in vivo that the intramuscular introduction of 
Pam2cSK4 results in greater tumor resistance to the 
action of 5-fluorouracil, enhancement of tumor growth, 
and a reduction in the survival rate of mice. An analysis 
of the mechanism of the previously described effect of 
the tLr2 agonist on WeHI-3B cells demonstrated that 
the activation of the nF-kB factor, as well as the stimu-
lation of the secretion of a number of pro-inflammatory 
cytokines (which are growth and development factors 
of myelomonocytic tumors), plays the key role in faster 
tumor progression.
EXPERIMENTAL
Cell lines
tLr2 expression was analyzed in the myelomonocytic 
mouse leukaemia cell line WeHI-3B, transformed reSeArcH ArtIcLeS
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murine macrophages В10М, murine fibroblasts L929, 
human leukaemic monocyte lymphoma u937 cells, hu-
man lung cancer cellsA549 and H460, human nonsmall 
cell lung cancer H1299 cells, human large intestine 
cancer Hct116 cells, and human breast cancer McF-7 
cells. the following were analyzed in WeHI-3B cells:   
the activity of nF-kB, caspases-3/7, viability, the mi-
tochondrial transmembrane potential, and the prolif-
eration rate.  
WeHI-3B cells were cultured in a rPMI medium 
with 10 vol % of fetal bovine serum (catalogue number 
SV30160.03, Hyclone, uSA), 1 mg/ml glutamine (cat-
alogue number F032, Paneco, russia), 50 u/ml peni-
cillin, and 50 µg/ml streptomycin (catalogue number 
A065, Paneco, russia) at 37°С in 5% cO2. cells were 
seeded at a 1 : 6 ratio on day 2.
Bacterial strains
the micoplasma strain Mycoplasma arginini used in 
this study was kindly provided by I.V. rakovskaya 
(Laboratory of Mycoplasmas and Bacterial L-Forms, 
Gamaleya research Institute of epidemiology and 
Microbiology, russian Academy of Medical Sciences). A 
flow cytometry kit (Bender Medsystems Flowcytomix, 
Austria) was used to determine the concentrations of 
chemokine and cytokine.
Reverse transcription reaction
the expression of TLR2 genes in different human/
murine cell lines was determined by rt-Pcr. the total 
rnA was isolated using trIZOL reagent (Invitrogen). 
the reverse transcription reaction was performed us-
ing an rt System kit (Promega). cDnA of the human/
mouse TLR2 and GAPDH genes were Pcr-amplified 
using the following primers: mouse TLR2 gene – up-
stream primer 5’-gtttccttctgaccaggatc-3’, downstream 
primer 5’-gcagcatcattgttctcttc-3’; human TLR2 gene 
– upstream primer 5’-acctgtgtgactctccatcc-3’, down-
stream primer 5’-gcagcatcattgttctcttc-3’; human 
GAPDH gene – upstream primer 5’-tctagacggcag-
gtcaggtccacc-3’, downstream primer 5’-ccacccat-
ggcaaattccatggca-3’; mouse GAPDH gene – upstream 
primer 5’-gcatcttcttgtgcagtgcc-3’, downstream primer 
5’-tcacacccatcacaaacatg-3’.
Measurement of β-galactosidase activity 
the culture medium was removed 24 h after the 
specimens had been added to the cells, and a lysis 
solution with β-galactosidase  substrate  (1  mM 
Mgcl2; 0.25 M tris-Hcl pH 7.4; 0.02% nP40; 2 g/l 
o-nitrophenyl-β-D-galactopyranoside  (catalogue 
number 102473, MP Biomedicals, uSA) was then add-
ed. β-galactosidase activity was determined spectro-
photometrically (414 nm) based on the conversion of 
the substrate (o-nitrophenyl-β-D-galactopyranoside) 
into the colored product o-nitrophenol.
Cell viability analysis
cell survival was assessed based on the ratio (%) be-
tween the intensity of the cells stained with methylene 
blue (pre-treated with cisplatin, taxol, and fluorouracil 
at varying concentrations) and the control, untreated 
cells (methylene blue was extracted with 0.1% SDS, its 
amount was determined chromatographically).
Caspases-3/7 activity measurement
the measurement of caspase activity was performed 
with the use of a specific to caspase-3/7 fluorogenic 
substrate Ac-DeVD-AMc (30 µM in lysis buffer pH 7.0 
containing 10 mM HePeS, 0.4 mM eDtA, 0.1% cHAPS, 
2% glycerol, and 2 mM Dtt). cells were incubated for 
16 h with apoptosis-inducing drugs. the fluorescence 
intensity was measured immediately (after 0 h) and 6h 
after additions of a substrate. the measurement was 
performed using a Wallac 1420 plate reader (Perkin 
elmer).
Measurement of the level of mitochondrial 
transmembrane potential (Δψm)
the level of the mitochondrial transmembrane poten-
tial (Δψm) was assessed on the basis of the binding of the 
fluorogenic dye Dioc6 (Sigma, uSA), of which the de-
gree of specific binding with mitochondrial membranes 
is dependent upon the Δψm value. the cells infected with 
M. arginini were placed into a 24-well plate (105 cells 
per well). Dioc6 at a concentration of 40 nM was added 
to the cells following apoptosis induction. the cells were 
incubated for 30 min at +370С and washed twice with a 
phosphate buffer. the fluorescence was then measured 
using a Wallac 1420 plate reader.
Measurement of cytokine activity
BALB/c mice received 5 µg of Pam2cSK4 intramus-
cularly. Blood samples were collected, and the concen-
trations of 14 chemokines and cytokines (IL-1, -2, -4, 
-5, -6, -10 and -12, tnFα, McP-1 and -3, MIP-1a, -1b, 
rAnteS, interferon-γ) were determined in serum by 
flow cytometry using a Flowcytomix BenderMedsys-
tems kit (Austria).
Laboratory animals
Six-week-old (by the beginning of the experiment) fe-
male BALB/c mice and D2&I thymus-free mice were 
used for this study.
Analysis of the survival rate of BALB/c mice
In order to assess the effect of diacylated lipopeptide 
Pam2cSK4 on the rate of tumor progression, WeHI-3B 86 | ActA nAturAe |  VOL. 3  № 4 (11)  2011
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cells (2 × 106 cells per mouse) were introduced intraperi-
toneally to BALB/c mice, which had been divided into 
different groups. 5 µg of Pam2cSK4 was introduced 
into each mouse at intervals of 1, 3, and 5 days post tu-
mor transplantation. After 20 days, the mice were eu-
thanized with diethyl ether; the liver and spleen were 
removed so as to be used for the macroscopic and his-
tological analysis. In addition, the average weight of the 
spleen for each experimental group was determined.
the effect of the joint introduction of Pam2cSK4 and 
tumor cells on the animals survival rate was studied on 
BALB/c mice, to which WeHI-3B cells (2 × 106 cells per 
mouse) were intraperitoneally transplanted. Synthetic 
diacylated lipopeptide (Pam2cSK4) was systemically 
introduced at a dose of 5 µg/mouse after 24 h. After 
2 days, the mice also received Pam2cSK4 for a period 
of 3 days; the mice from the groups subjected to chem-
otherapy additionally received 0.6 mg of 5-fluorouracil. 
the control groups consisted of the animals that had re-
ceived Pam2cSK4 and 5-fluorouracil only. each group 
consisted of 10 mice. the animals were monitored until 
the death of the final mouse (32 days); the general con-
dition of the mice was recorded.
RESULTS AND DISCUSSION
Analysis of the expression of the Toll-like 
receptors 2 and 6 in different tumor cell lines
the model we used to study the effect of tLr2 on the 
proliferation of tumor cells and on tumor progression 
in vivo was selected via an analysis of the expression 
of the toll-like receptor 2 in different tumor cell lines 
(WeHI-3B, B10M, L929, u937, A549, H460, H1299, 
Hct116, and McF-7) by reverse transcription followed 
by Pcr against the TLR2 gene (Fig. 1).
the toll-like receptor 2 was expressed in five out 
of the nine cell lines analysed (WeHI-3B, B10M, u937, 
H1299 and McF-7). the highest level of expression 
of this receptor was observed in the myelomonocytic 
mouse leukaemia cell line (WeHI-3B), which was sub-
sequently selected for use as a model for the in vitro 
and in vivo experiments.
TLR2 agonist activates NF-kB and 
suppresses apoptosis in tumor cells WEHI-
3B expressing Toll-like receptor 2
Such parameters as the nF-kB factor activity (Fig. 2), 
cell survival rate, caspases-3/7 level (Fig. 3), and the 
level of the mitochondrial transmembrane potential 
(Δψm) (Fig. 4) were measured at the next stage of the 
assessment of the effect of tLr2 agonists on apoptosis 
induced by chemotherapy drugs in WeHI-3B cells ex-
pressing the toll-like receptor 2. WeHI-3B cells were 
infected with M. arginini, or the tLr2 agonist (syn-
thetic diacylated lipopeptide Pam2cSK4) was added 
followed by treatment with cisplatin, taxol or fluorour-
acil. the parameters mentioned above were measured 
after 16–18 h of incubation.
It was demonstrated that micoplasma infection of 
the tumor cells WeHI-3B containing the toll-like re-
ceptor 2 resulted in the activation of the transcription 
factor nF-kB in these cells (Fig. 2). Similar results were 
obtained when synthetic diacylated lipopeptide was 
added to Pam2cSK4.
Figure 2A shows the data obtained by flow cytom-
etry using specific antibodies to tLr2, which confirm 
the expression of tLr2, the major receptor of mico-
plasmal diacylated lipopeptides, and the data on the 
activation of nF-kB in WeHI-3B cells via the tLr2-
dependent pathway (Fig. 2B).
Figure 3 shows the survival rate and activity level 
of the major effector caspases-3/7 upon induction of 
apoptosis by chemotherapeutical drugs in WeHI-3B 
cells infected with M. arginini, or upon the addition 
of Pam2cSK4 to these cells. the level of caspases-3/7 
was measured spectrophotometrically, using the spe-
cific fluorogenic substrate Ac-DeVD-AMc. As follows 
from these data, mycoplasma infection or the addi-
tion of lipopeptide Pam2cSK4 results in a statistically 
significant (р < 0.005) increase in the survival rate of 
WeHI-3B cells and a 25–30% decrease in the level of 
caspase-3/7 activation upon various intracellular dam-
ages in comparison with noninfected cells (white bars).
the mitochondrial transmembrane potential (Δψm) 
was also measured in WeHI-3B cells; a decrease in this 
potential caused by various stress factors is the major 
apoptotic marker.
For this purpose, different concentrations of cisplatin 
were used to affect the infected or Pam2cSK4-treated 
cells; the level of the mitochondrial transmembrane po-
tential (Δψm) was measured after 16 h (Fig. 4).
the level of Δψm was assessed based on the binding of 
the fluorogenic dye Dioc6, the degree of specific bind-
ing to mitochondrial membranes, which is dependent 
upon Δψm.
As can be seen from the data presented, the level 
of mitochondrial transmembrane potential in cispla-
TLR2
GAPDH
WEHI-3B  B10М  L929  U937  A549  H460  H1299  HCT116  MCF-7
Fig. 1. Analysis of TLR2 expression in different tumor cell 
lines.reSeArcH ArtIcLeS
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tin-treated WeHI-3B cells infected with M. аrginini 
was higher by 25–30% than that of the noninfected 
cells (white bars), a point attesting to apoptosis sup-
pression in the infected cells. Similar results were also 
obtained when using the synthetic diacylated peptide 
Pam2cSK4.
thus, it was demonstrated in the first path of the 
in vitro experiment that micoplasma infection or the 
addition of structural micoplasmal components to We-
HI-3B cells expressing the toll-like receptors 2 and 6 
results in the activation of the transcription factor nF-
kB in them and apoptosis suppression upon different 
types of intracellular damage.
Kinetics of the growth of tumor cells WEHI-3B 
upon infection with M. arginini, or upon addition 
of diacylated lipopeptide Pam2CSK4 in the in vitro 
experiment
the transcription factor nF-kB participates in the 
regulation of the expression of a number of proteins, 
including those controlling cell proliferation and apop-
tosis [19].
At the next stage of the study, we decided to observe 
the level of the impact that the micoplasmal infection 
or structural micoplasmal components, together with 
the anti-apoptotic activity, can have on both the kinet-
ics and proliferation rates of the tumor cells WeHI-3B 
under normal conditions and/or upon the induction of 
apoptosis in them.
For this purpose, M. arginini or Pam2cSK4 was 
added to the WeHI-3B cell line selected as a model; 
the activation of nf-kB in these cells was verified. the 
cells were then seeded into a 96-well plate (103 cells 
per well), and apoptosis-inducing drugs (cisplatin and 
taxol) were added. the kinetics of cell growth was de-
termined based on the accumulation of cell biomass 
(methylene blue staining) for 72 h (with or without the 
apoptosis stimulus).
It follows from Fig. 5 that apoptosis blockage was ob-
served in micoplasma-infected cells with and/or upon 
addition of Pam2cSK4. However, no increase in the 
proliferation rate was observed.
It was thus demonstrated that apoptosis suppression 
in micoplasma-infected cells caused by the activation 
of the transcription factor nF-kB does not result in an 
in vitro increase in the cell proliferation rate.
The effect of the TLR2 agonist – diacylated 
lipopeptide Pam2CSK4 – on the proliferation and 
resistance of WEHI-3B cells to chemotherapeutic 
agents in an in vivo experiment
the effect of the antigens circulating in the mouse’s 
organism (tLr2 agonists) on the proliferation and re-
sistance of the myelomonocytic mouse leukaemia cells 
Fig. 2. Activation of NF-kB in WEHI-3B cells in response to mycoplasmal infection or after treatment with diacylated 
lipopeptide Pam2CSK4. (А) – TLR2 expression in WEHI-3B cells. Expression of the specific for diacylated lipopeptides 
receptor TLR2 was additionally confirmed by flow cytometry. WEHI-3B cells were incubated with antibodies specific to 
mouse TLR2 (eBioscience, USA). Control cells were incubated with isotype control antibody (anti-IgG). The percent-
age of TLR2 positive cells was determined by phycoerythrin fluorescence (the assay was conducted according to the 
manufacture manual). (B) – NF-kB-dependent expression of luciferase gene. Luciferase gene under NF-kB – responsive 
promoter was introduced in WEHI-3B cells by lentiviral infection. NF-kB-dependent luciferase expression was measured 
using the standard procedure after m. arginini infection or treating the cells with diacylated lipopeptide Pam2CSK4.
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WeHI-3B to chemotherapeutic agents in vivo was 
studied.
Firstly, the effect of the diacylated lipopeptide 
Pam2cSK4 on the rate of tumor progression was as-
sessed. Forty 18–20 g animals (female BALB/c mice) 
participated in the experiment. the animals were di-
vided into four groups, 10 mice per group. the con-
trol group (the first group) consisted of intact mice. 
the second group included mice that received three 
doses of Pam2cSK4 intramuscularly. the third group 
was comprised of the mice transplanted with WeHI-
3B cells (2 × 106 cells per mouse). the mice from the 
fourth group were intraperitoneally transplanted with 
WeHI-3B cells of identical dose. each mouse from this 
group received 5 µg of Pam2cSK4 on days 1, 3, and 5 
following tumor transplantation. the mice were eutha-
nized with diethyl ether in order to assess the tumor 
progression after 20 days; the liver and spleen were 
removed from the mice and were subsequently used 
for macroscopic and histological studies. the average 
weight of the spleen was determined in each experi-
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mental group (Fig. 6A–B). According to the data ob-
tained in the macroscopic study, no visible pathological 
changes were observed in mice from groups 1 and 2 
(Fig. 6A). However, a negligible increase in the average 
weight of the spleen was observed in mice from group 2 
(Fig. 6B). the changes typical of leukaemia (increase of 
spleen size and slightly swollen liver) were detected in 
the liver and spleen of the mice with transplanted my-
elomonocytic mouse leukaemia cells (group 3) by mac-
roscopic studies. Sparse tumors were detected on the 
liver and spleen surface. When performing the mac-
roscopic study of the liver and spleen obtained from 
mice transplanted with leukaemia cells and that had 
received Pam2cSK4 (group 4), the changes typical of 
leukaemia were also observed. the spleen was consid-
erably swollen. Loose neo-formations (which turned 
out to be myelomonocytic leukaemia cells) were found 
on the spleen and liver surface.
the measurements of the average weight of the 
spleen demonstrated a significant increase in the weight 
of this organ in mice with leukaemia (groups 3 and 4) as 
compared to the mice from the control groups 1 and 2. 
the introduction of Pam2cSK4 to mice from group 4 
resulted in an even greater increase in the average 
weight of the spleen (p < 0.05) in comparison with the 
animals from group 3 (Fig. 6B).
no pathological changes were revealed in a histo-
logical study of the spleen and liver of the mice from 
groups 1 and 2. An identical pattern was observed in 
the spleen of the mice from groups 3 and 4. Diffuse 
dense infiltration of pulp with myelomonocytic leu-
kaemia elements was observed; lymphatic follicles 
were atrophied. the greatest differences were ob-
served between the liver samples of the mice from 
groups 3 and 4. numerous small myelomonocytic 
leukaemia infiltrates were present in the livers of 
the mice from group 3, whereas the mice livers from 
group 4 were considerably larger (Fig. 6C). Infiltrates 
mostly localized along sinusoids. Leukaemia cell ag-
gregation was also detected in individual blood vessels. 
A clearly defined surface infiltration of a liver with 
leukaemia cells was observed in mice from group 4, in 
contrast to those from group 3.
the macro- and microscopic studies of spleen and 
liver samples obtained from mice which were intra-
peritoneally transplanted with WeHI-3B cells allowed 
us to arrive at the conclusion that micoplasma diacylat-
ed lipopeptide promotes tumor progression.
the effect of the diacylated lipopeptide Pam2cSK4 
on the rate of tumor progression was assessed at the 
next stage. the nature of the effect of Pam2cSK4 on 
the resistance of the transplanted cells to chemother-
apeutic agents was simultaneously determined. this 
experiment was performed according to the scheme 
described in the experimental section. Figure 6D shows 
the diagram of the survival rate of the experimental 
mice.
It was shown via an analysis of the Kaplan–Meier 
survival curves that the mice receiving the synthetic 
diacylated lipopeptide demonstrated a less favorable 
response to 5-fluorouracil in comparison with those that 
did not receive Pam2cSK4. the last mouse from the 
group receiving chemotherapy died on day 33, whereas 
the mice that received Pam2cSK4 simultaneously with 
chemotherapy died as early as on day 26.
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the in vivo survival rate of mice was in complete 
correlation with the results previously obtained on cul-
ture cells. Moreover, as follows from the diagram, all 
mice into which WeHI-3B and Pam2cSK4 cells were 
simultaneously introduced died as early as on day 19, 
whereas the lifetime of those mice that did not receive 
Pam2cSK4 was equal to 25 days. these data attest 
to the fact that the intramuscular administration of 
Pam2cSK4 results in accentuated tumor progression 
and a decrease in the lifetime of mice. It is noteworthy 
that these experimental results showed no agreement 
with the data obtained for a cell culture, where the ad-
dition of Pam2cSK4 into the culturе media did not re-
sult in an increase in the proliferation rate of WeHI-3B 
cells.
The effect of diacylated lipopeptide Pam2CSK4 
on production of the factors stimulating 
the in vivo proliferation of myelomonocytic 
mouse leukaemia cells WEHI-3B
taking into account the major difference between the 
in vitro and in vivo growth of WeHI-3B cells in the 
presence of Pam2cSK4, it was assumed that the fac-
tors that are essential for the proliferation of WeHI-
3B cells can occur in the organism of the experimental 
animals after diacylated lipopeptide is introduced, thus 
determining the kinetics of the in vivo growth of these 
cells.
to corroborate this hypothesis, we studied the ef-
fect of serum obtained from the mice that had received 
Pam2cSK4 on the proliferation rate of WeHI-3B 
cells. BALB/c mice received intramuscular injections 
of 5 µg of diacylated lipopeptide Pam2cSK4. twen-
ty-four hours after the injection, blood samples were 
taken to obtain serum. Serum from mice that received 
a phosphate saline buffer was used as a control. the 
sera were used to prepare 5% of the medium for cultur-
ing WeHI-3B (rPMI) cells. the media were added to 
WeHI-3B cells, which were then seeded into a 96-well 
plate at a concentration of 103 cells per well. the kinet-
ics of cell growth was determined based on the accu-
mulation of cell biomass in the reaction with the Mtt 
substrate during 72 h (Fig. 7).
As follows from Fig. 7, the addition of blood serum 
obtained from the mice that intramuscularly received 
Pam2cSK4 to WeHI-3B cells resulted in an increase in 
their proliferation rate. the results of this experiment 
corroborated the assumption earlier made about the 
possible production of the factor inducing the growth 
of the myelomonocytic mouse leukaemia cells WeHI-
3B in response to the introduction of Pam2cSK4.
An attempt to identify the factors promoting the ac-
centuated growth of WeHI-3B cells was undertaken at 
the next stage.
For this purpose, the synthesis of chemokines and 
cytokines in the organism in response to the introduc-
tion of diacylated lipopeptide was analyzed (Fig. 8). 
the cytokine expression was determined according 
to the procedure described in the experimental sec-
tion. Figure 8 shows the data for cytokines whose ex-
pression level changed in response to the introduc-
tion of Pam2cSK4. It is clear that the introduction of 
Pam2cSK4 resulted in a change in the expression of 
eight of the 14 cytokines. An analysis of the published 
data demonstrated that five of these cytokines (IL-6, 
McP-1, McP-3, rAnteS, and tnFα) are capable of 
direct or indirect promotion of tumor growth [21].
Hence, it was shown that the activation of the tLr2-
dependent signalling pathway in WeHI-3B cells after 
the introduction of diacylated lipopeptide Pam2cSK4 
or M. arginini cells leads to the constitutive activation 
of the transcription factor nF-kB in WeHI-3B cells. In 
turn, the activation of nF-kB results in increased re-
sistance of these cells to various assaults induced by 
chemotherapeutic agents (cispatin, taxol, and fluorou-
racil).
It was demonstrated via in vitro experiments that 
apoptosis suppression in the cells infected with M. ar-
ginini, which was caused by the activation of the tran-
scription factor nF-kB, had no effect on the rate of 
cell proliferation. However, the data obtained in vivo 
differs: the intramuscular introduction of Pam2cSK4 
promoted the growth of myelomonocytic mouse leu-
kaemia cells WeHI-3B in the organism of experimental 
animals. this fact is mostly accounted for by the ability 
of Pam2cSK4 to stimulate the expression of the factors 
(IL-6, McP-1, McP-3, rAnteS, and tnFα) boosting 
the growth of tumor cells.
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the results obtained for the model WeHI-3B cells 
show that the activation of the toll-like receptor 2 in 
tumor cells of myelomonocytic origin caused by myco-
plasmal infection or the direct action of the tLr2 ago-
nist (diacylated lipopeptide) promotes the growth of 
these cells. Meanwhile, studying the effect of mycoplas-
ma and its structural component diacylated lipopeptide 
Pam2cSK4 on the development of the tumor allows 
one to arrive at the conclusion that the mycoplasmal in-
fection may impact not only the rate of disease progres-
sion, but also the effectiveness of anti-tumor therapy. 
this observation is valid not only for mycoplasmas, but 
also for the other pathogens causing various infections 
in patients with malignancies. the potential exists to 
conduct efficient therapy in the case of myelomono-
cytic leukaemias, provided that the disease is not stim-
ulated by the factors of pathogenic microorganisms, or 
their antigens, circulating in the body. 
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